Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1492 of 5804
-
New hope for HER2 cancers: first human trial launches
Disease control Recruiting nowThis first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control OngoingA Phase I/II, Open-Label, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of LM-108, an Anti-CCR8 Monoclonal Antibody, as Monotherapy or in Combination with Antitumor Therapies in Patients wi…
Phase: PHASE1, PHASE2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Can High-Flow oxygen at home prevent COPD Flare-Ups?
Disease control Recruiting nowThe objective of the study is to evaluate the efficacy of home High Flow Oxygen for the reduction of severe exacerbation following admission for a severe exacerbation of COPD or death against standard oxygen therapy.
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New quick memory check could help detect dementia early in routine doctor visits
Diagnosis OngoingOur study objective is to widely implement and evaluate a user-centered, scalable, electronic health record (EHR)-linked strategy for the routine detection of cognitive decline among diverse primary care settings. This strategy, called ToolboxDetect, will provide an efficient and…
Phase: NA • Sponsor: Northwestern University • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
Shining a light on depression: new therapy shows promise
Symptom relief CompletedMajor depressive disorder (MDD) is a leading cause of disability worldwide, and many patients do not achieve adequate benefit from current treatments. Transcranial photobiomodulation (tPBM) is a non-invasive neuromodulation technique that delivers near-infrared (808 nm) light thr…
Phase: NA • Sponsor: NeuroThera DE • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Gene therapy trial aims to repair hearts in rare neurological disease
Disease control OngoingThis is a Phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of LX2006 for participants who have Friedreich's Ataxia with evidence of cardiomyopathy. The study will evaluate up to three doses of single administration of LX2006 (AAVrh.10hFXN), an a…
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New inhaled drug shows promise for rare lung condition
Disease control CompletedThe main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
Phase: PHASE2 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug cocktail aims to tackle tough lung cancer
Disease control OngoingThis is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for rare sarcomas: targeted pill attacks Cancer's DNA repair
Disease control OngoingThe purpose of this study is to test whether the study drug, niraparib, is effective against unresectable and/or metastatic soft tissue sarcoma with DDR mutations. The researchers will also study whether niraparib is safe and causes few or mild side effects, and whether there are…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy targets untreatable liver tumors
Disease control Recruiting nowThis research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab with stereotactic body radiation therapy (SBRT) for treating unresectable hepatocellular carcinoma. This study involves the following interventions: * Atezolizumab * Bevacizu…
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could a simple heart monitor cut deaths in shock patients?
Disease control Recruiting nowThe primary objective of the PACCS trial is to assess if early invasive hemodynamic assessment and ongoing management with a PAC in patients with cardiogenic shock due to acutely decompensated heart failure (AHDF-CS) is associated with lower in-hospital mortality risk compared to…
Phase: NA • Sponsor: Tufts Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Smart radiation aims to zap prostate cancer recurrence with fewer side effects
Disease control Recruiting nowThis is a Phase II prospective single-arm trial that is recruiting 80 participants from patients that have biochemical failure after radical prostatectomy with local or regional recurrence proven by PSMA PET. Participants of this study will receive molecular imaging informed radi…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Blood test could spot cancer return months before scans
Diagnosis Recruiting nowPreoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse du…
Phase: NA • Sponsor: Masaryk Memorial Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy targets tough colorectal cancer
Disease control TerminatedDoctors leading this study hope to learn about the safety of combining the study drug VS-6766 with another drug called cetuximab in colorectal cancer. This study is for individuals who have advanced colorectal cancer and their cancer has progressed while getting previous treatmen…
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New disc implant aims to ease chronic back pain without fusion
Disease control Recruiting nowThis study will be a prospective, open-label, multi-center study including 72 patients that will collect additional safety and efficacy data for the Spinal Stabilization Technologies PerQdisc Nucleus Replacement System.
Phase: NA • Sponsor: Spinal Stabilization Technologies • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Head exercises may cut falls in Alzheimer's patients
Symptom relief Recruiting nowNearly 2 out of 3 patients with Alzheimer's disease (AD) experience problems with balance and mobility, which places such patients at increased risk of falling. The vestibular (inner ear balance) system plays an important role in balance stability, and vestibular therapy (VT) is …
Phase: NA • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Old drug, new hope: doxycycline tested for HIV-Related emphysema
Disease control OngoingThe purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ra…
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New HIV vaccine strategy aims to trigger powerful antibodies
⭐️ VACCINE ⭐️ CompletedThe clinical study is designed to evaluate the ability of two priming vaccine regimens to activate and induce the maturation of cross-reactive CD4 binding site (CD4-bs) antibodies, including VRC01-class antibodies. VRC01- class antibodies are highly desirable to elicit via vaccin…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 10, 2026 00:00 UTC
-
New pill aims to tackle fatty liver and diabetes at once
Disease control OngoingThe design of the Phase 2 clinical trial includes the following elements: * Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs. placebo in approximately 40 patients in the U.S. * Patients will be randomized 1:1 to receive…
Phase: PHASE2 • Sponsor: MediciNova • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New cocktail of drugs shows promise for tough pancreatic cancer
Disease control CompletedThe purpose of this study is to evaluate the safety and clinical activity of tadalafil, pembrolizumab, ipilimumab, and CRS-207 in subjects with metastatic pancreatic adenocarcinoma who have progressed after at least 1 prior chemotherapy regimen.
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC